Revenue Growth
RMD's revenue increased by 10.8% year-over-year, driven by strong sales performance across key markets.
Source: 10-Q Income Statement
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
RMD reported strong financial performance in Q3 FY2026, with significant revenue growth and improved margins, driven by increased sales and effective cost management.
Revenue
$1.43B
+10.81% YoY
EPS (Diluted)
$2.74
+10.48% YoY
Gross Margin
62.2%
+2.9 pts YoY
Operating Income
$499.81M
+17.25% YoY
Source: SEC XBRL
Resmed (RMD) reported Q3 FY2026 revenue of $1.43B, up 10.8% year over year. Operating margin was 34.9%, up 1.9 points from 33.0% a year earlier. RMD's fiscal Q3 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 3 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 2.95 | 2.92 | Beat +1.1% |
| Mar 2026This filing | 2.86 | 2.82 | Beat +1.3% |
| Dec 2025 | 2.81 | 2.75 | Beat +2.1% |
| Sep 2025 | 2.55 | 2.58 | Miss -1.2% |
Adjusted (non-GAAP) EPS of $2.86 versus the $2.82 analyst consensus — a +1.3% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $2.74.
Compiled by AI from this SEC filing
RMD's revenue increased by 10.8% year-over-year, driven by strong sales performance across key markets.
Source: 10-Q Income Statement
Gross margin improved to 62.2%, reflecting better cost management and higher operational efficiency.
Source: 10-Q Income Statement
R&D expenses rose by 12.3%, indicating a focus on innovation and product development.
Source: 10-Q Income Statement
Compiled by AI from this SEC filing · 1 high, 2 medium, 0 low
Potential disruptions in the supply chain could impact production and delivery schedules, affecting revenue and profitability.
Source: Industry Analysis
Fluctuations in foreign exchange rates may adversely affect the company's international revenue and profitability.
Source: Industry Analysis
Changes in industry regulations could impose additional compliance costs and operational challenges.
Source: Industry Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 1.43 $B | 1.29 $B | +10.81% |
Cost of Revenue $M | 540.43 $M | 525.33 $M | +2.87% |
Gross Profit $M | 890.98 $M | 766.41 $M | +16.25% |
Operating Income $M | 499.81 $M | 426.27 $M | +17.25% |
Net Income $M | 398.73 $M | 365.04 $M | +9.23% |
EPS (Basic) $ | 2.74 $ | 2.49 $ | +10.04% |
EPS (Diluted) $ | 2.74 $ | 2.48 $ | +10.48% |
R&D Expense $M | 94.27 $M | 83.94 $M | +12.30% |
SG&A Expense $M | 285.66 $M | 245.30 $M | +16.45% |
Answers draw on this SEC filing and the data on this page
ResMed delivered roughly 10% revenue and diluted EPS growth in fiscal 2026 on strong sleep device and mask demand, but a higher effective tax rate held net income growth to single digits.
RMD reported strong financial performance in Q2 FY2026 with significant growth in revenue and net income, driven by increased operational efficiency and robust market demand.
Other companies in Health Care Equipment